Monte Rosa Therapeutics (GLUE) Non Operating Income (2020 - 2026)

Monte Rosa Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 62.58% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $15.1 million (up 26.32% YoY), while the FY2025 annual figure was $12.9 million, up 17.85% from the prior year.
• Non Operating Income for Q1 2026 stood at $5.6 million, up from $3.7 million in the prior quarter.
• The five-year high for Non Operating Income was $5.6 million in Q1 2026, with the low at $149000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.6 million (2024), against an average of $2.5 million.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income soared 4385.71% in 2022, then dropped 20.15% in 2023.
• Monte Rosa Therapeutics' Non Operating Income stood at $2.0 million in 2022, then decreased by 20.15% to $1.6 million in 2023, then surged by 89.49% to $3.0 million in 2024, then gained by 22.52% to $3.7 million in 2025, then soared by 51.56% to $5.6 million in 2026.
• Business Quant data shows GLUE's Non Operating Income at $5.6 million in Q1 2026, $3.7 million in Q4 2025, and $2.7 million in Q3 2025.